MaxCyte (MXCT) vs TriSalus Life Sciences (TLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
TriSalus Life Sciences (TLSI) has outperformed MaxCyte (MXCT) over the past year, losing 14.8% versus a loss of 40.0%. Over five years, TLSI leads with a -58.3% price change compared with -90.8% for MXCT. TriSalus Life Sciences is the larger company by market cap ($254.3 million vs $105.3 million), about 2.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MXCT | TLSI |
|---|---|---|
| Share price | $1.02 | $4.13 |
| Market cap | $105.27M | $254.30M |
| 1-day change | -1.92% | -2.82% |
| YTD return | -34.19% | -40.83% |
| 1-year return | -40.00% | -14.85% |
| 5-year return | -90.75% | -58.28% |
| EPS (TTM) | $-0.34 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.87 | $7.95 |
| 52-week low | $0.643 | $2.20 |
| Distance from 52-week high | -45.31% | -48.05% |
| Analyst consensus | none | none |
| Avg. price target upside | +302.94% | +151.82% |
| Average volume | 668.82K | 275.38K |
| Shares outstanding | 103.21M | 61.57M |
| Employees | 91 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TriSalus Life Sciences is about 2.4 times larger than MaxCyte by market value ($254.30M vs $105.27M).
- TLSI has outperformed MXCT by 25.2 percentage points over the past year.
About MaxCyte
MXCT stock →MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 91 employees
About TriSalus Life Sciences
TLSI stock →TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
Health Care · Medical Specialities · 102 employees
MXCT vs TLSI FAQ
Which is bigger, MaxCyte or TriSalus Life Sciences?
TriSalus Life Sciences (TLSI) is larger, with a market capitalization of $254.30M compared with $105.27M for MaxCyte (MXCT).
Which stock has performed better over the past year, MXCT or TLSI?
TLSI returned -14.85% over the past 12 months, compared with -40.00% for MXCT (price return, excluding dividends). Past performance does not predict future results.
Are MaxCyte and TriSalus Life Sciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for MaxCyte and Medical Specialities for TriSalus Life Sciences.